This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Restifo, N., Dudley, M. E. & SA, R. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12, 269–281 (2012).
Stauss, H. J. et al. Monoclonal T-cell receptors: new reagents for cancer therapy. Mol. Ther. 15, 1744–1750 (2007).
Kershaw, M. H., Westwood, J. A. & Darcy, P. K. Gene-engineered T cells for cancer therapy. Nat. Rev. Cancer 13, 525–541 (2013).
Lim, W. & CH, J. The principles of engineering immune cells to treat. Cancer Cell 168, 724–740 (2017).
Rapoport, A. P. et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 21, 914–921 (2015).
van Loenen, M. M. et al. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc. Natl Acad. Sci. USA 107, 10972–10977 (2010).
Aggen, D. H. et al. Single-chain VαVβ T cell receptors function without mispairing with endogenous TCR chains. Gene Ther. 19, 365–374 (2012).
Voss, R. H. et al. Coexpression of the T-cell receptor constant alpha domain triggers tumor reactivity of single-chain TCR-transduced human T cells. Blood 115, 5154–5163 (2010).
Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 543, 113–117 (2017).
Xue, S. A. et al. Human MHC Class I-restricted high avidity CD4(+) T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. Oncoimmunology 2, e22590 (2013).
Acknowledgements
This work was supported by Blood Wise (H.J.S. and E.M.), the National Natural Science Foundation of China (NSFC-81972883: S.A.X. and Y.C.), the Social Development & Scientific Technology Key Project of Shaanxi Province (2016SF-079: S.A.X.) and the Scientific Technology Program & Innovation Fund of the Xi’An City Special Project (CXY1531WL12: S.A.X.). We would like to thank Professor Benny Chain for providing Jurkat cells for the study.
Author information
Authors and Affiliations
Contributions
S.A.X., Y.C., V.K., B.W., K.K.C., F.Q.H., X.X.C., L.S., A.H., and L.G. performed the research; S.A.X., Y.C., V.K., and B.W. analyzed the data; S.A.X., R.H.V., and H.J.S. designed the experiments; E.M. and H.J.S. supervised the study; S.A.X. and Y.C. wrote the paper; and R.H.V. and H.J.S. reviewed the paper.
Corresponding authors
Ethics declarations
Competing interests
S.A.X., R.H.V., and H.J.S. are inventors on patents describing the Sc-TCR technology. The remaining authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Xue, SA., Chen, Y., Voss, RH. et al. Enhancing the expression and function of an EBV-TCR on engineered T cells by combining Sc-TCR design with CRISPR editing to prevent mispairing. Cell Mol Immunol 17, 1275–1277 (2020). https://doi.org/10.1038/s41423-020-0396-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41423-020-0396-9
This article is cited by
-
Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy
Molecular Biology Reports (2022)